Evidence map›Paper›PMID 35758824›Full record

ArticleThe CRISPR journal2022

Enhanced Myogenesis by Silencing Myostatin with Nonviral Delivery of a dCas9 Ribonucleoprotein Complex.

Yinwei Chen, Lia Banie, Benjamin N Breyer, Yan Tan, Zhao Wang, Feng Zhou, Guifang Wang, Guiting Lin, Jihong Liu, Lei S Qi and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The CRISPR journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Yinwei ChenKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Lia BanieKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Benjamin N BreyerKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Yan TanKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Zhao WangKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Feng ZhouKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Guifang WangKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
Guiting LinKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.ORCID 0000-0001-7518-0788
Jihong LiuDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Stanford University, Stanford, California, USA.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, California, USA; and Stanford University, Stanford, California, USA.ORCID 0000-0002-3965-3223
Tom F LueKnuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; Stanford University, Stanford, California, USA.
University of California, San Francisco · USStanford University · USTongji Hospital · CN

Funding

Regenerative therapy for stress urinary incontinence and pelvic floor disorderR01DK124609 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LUE, TOM F · 2020 to 2023
$2.3M
NIDDK NIH HHS R01 DK124609
6 · The paper itself

Abstract

Stress urinary incontinence (SUI) and pelvic floor disorder (PFD) are common conditions with limited treatment options in women worldwide. Regenerative therapy to restore urethral striated and pelvic floor muscles represents a valuable therapeutic approach. We aim to determine the CRISPR interference-mediated gene silencing effect of the nonviral delivery of nuclease-deactivated dCas9 ribonucleoprotein (RNP) complex on muscle regeneration at the cellular and molecular level. We designed four myostatin (

Indexed as

CRISPR-Cas SystemsMuscle DevelopmentMyostatinUrinary Incontinence, StressAnimalsFemaleGene EditingGlycogen Synthase Kinase 3 betaHumansRatsRibonucleoproteinsGlycogen Synthase Kinase 3 betaMstn protein, ratMyostatinRibonucleoproteins

Identifiers

PMID35758824
PMCPMC9419946
OpenAlexW4283591190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.